Tuesday, September 19, 2017

National Defense Authorization Act, NDAA Conference Committee

The version of the National Defense Authorization Act (NDAA) passed September 18, 2017 by the Senate prohibits funding for medical research by DoD unless such research meets very narrowly defined criteria and places unnecessary and burdensome red-tape, acquisition, compliance and auditing requirements on research programs within the Department of Defense. The troublesome portions of the Senate version of the NDAA are Sections 733, 891, 892, and 893. 

I functioned as a reader (evaluator) in 2016 for MSRP Grant Applications and am a Veteran with a Multiple Sclerosis diagnosis (one of 20,000 veterans know to the VA with the diagnosis). We need the, "High Risk/High Reward" research the Congressionally Directed Medical Research Program (CDMRP) and the Multiple Sclerosis Research Program (MSRP) bring to the table in the ongoing effort to: STOP MS PROGRESSION, RESTORE PATIENT'S LOST FUNCTION and END MS FOREVER.   

I will call on each member of the NDAA Conference Committee to support striking Sections 733, 891, 892, and 893 of the Senate's NDAA Bill in any final version of the NDAA.

Stay tuned for more updates on this subject.

Tuesday, September 12, 2017

MRI Contrast Agent Warning

https://www.medpagetoday.com/Radiology/DiagnosticRadiology/67811?xid=nl_mpt_DHE_2017-09-12&eun=g351680d0r&pos=2


FDA Panel Backs New Warning for Gadolinium Contrast Agents
Manufacturers could be required to conduct new studies    
·         
b    By Shannon Firth, Washington Correspondent, MedPage Today
      September 11, 2017

SILVER SPRING, Md.

An FDA advisory committee voted 13-1, with one abstention, to recommend a new warning for gadolinium-based contrast agents (GBCAs) used in magnetic resonance imaging on Friday.
Specifically, the FDA's Medical Imaging Drugs Advisory Committee recommended that prescribing information should include "a warning for retention for all GBCAs with greater retention of all or some of the linear GBCAs compared to the macrocyclics in certain organs including the brain," and that "risk minimization steps" be taken for certain patient populations.
The FDA made a minor distinction between macrocyclic and linear GBCAs, noting the higher stability of the macrocyclics may cause them to "wash out" of the body; but the agency stressed that both agents leave behind deposits of gadolinium.
Agency leadership asked the committee for advice on how to weigh recent findings of gadolinium retention in the brain and other organs, and how to minimize potential risks moving forward.
Virtually all committee members agreed that the evidence of retention in patients, to date, doesn't indicate a definitive causal relationship with an array of symptoms reported in the FDA's database and medical literature, beyond previously identified concerns for kidney patients (current labeling already includes a boxed warning and contraindications for this population).
In 2007, researchers uncovered a link between GBCAs and nephrogenic systemic fibrosis (NSF) -- a debilitating condition, that impacts the skin, muscles and internal organs and is sometimes fatal -- in kidney patients, however more recent evidence suggests patients without impaired renal function also show deposits of gadolinium in their central nervous system and throughout the body. As recently as June, researchers reported that gadolinium deposits were found in patients with normal brains -- previously intracranial abnormalities were seen as responsible for the agents clinging to neural tissues.
Still, members voted unanimously to recommend the FDA consider requiring industry conduct more research to help the agency determine if regulatory action "including withdrawal of approval and restriction of indicated populations" is necessary.
Jeffrey Brent, MD, PhD, of the University of Pennsylvania, who backed the new warning, described the latest evidence of problems in patients without a serious renal condition as "anecdotal data." However, "there clearly is concern and people need to know."
"[P]eople need to know," said Alicia Toledano, ScD, president of Biostatistics Consulting LLC, from Kensington, Md., and the single "no" vote. She said the warning was not strong enough and would never be seen by most patients.
During the meeting, some macrocyclic makers sought to emphasize differences in the chemical structure between their products and linear contrast agents, which may lead to greater retention of linear products;while linear contrast agent manufacturers underscored that retention occurs with both classes, differences in retention are slight, and the threshold for toxicity is unclear.
In public testimony, Sharon Williams and Hubbs Grimm, who run The LightHouse Project, a support group for people who believe they have gadolinium toxicity. Williams and Grimm argued that if people without renal issues are also retaining gadolinium, it follow that they might have NSF-like symptoms.
"It makes no sense to think that there are only two options: NSF or nothing at all," Williams said.
Sammy Almashat, MD, MPH, a research associate for the consumer group Public Citizen, argued that if they knew the evidence regarding the differences between the two classes of contrast agents, "virtually all patients" would choose the macrocyclics. He, like Brent and Vaughan, argued for adopting the the European Medicines Agency's approach. That agency suspended certain GBCAs in July.
Concerns about gadolinium toxicity emerged over a decade ago, after some patients with renal failure developed Nephrogenic Systemic Fibrosis (NSF) and a link was found between the "debilitating" condition and GBCA used in MRIs.
In 2010, the FDA adopted safety label changes including a contraindication for patients with renal insufficiency, strengthened a boxed warning and precautions recommending limiting or "allow[ing] clearance" between doses, and screening vulnerable populations.
Then, in July 2015, the FDA issued a Drug Safety communication that noted reports of retention of gadolinium in the brain after the use of GBCAs, which underscored the increased retention with linear GBCAs compared to macrocyclic GBCAs.
In that communication the FDA urged physicians to limit the use of such agents to "clinical circumstances in which the additional information provided by the contrast is necessary," also urging them to reassess the necessity of repetitive contrast MRIs in established treatment protocols.
In 2016, manufacturer Optimark, requested label changes to include mention that "retention may be greater with linear GBCAs than macrocyclic GBCAs."
On May 22, 2017, the FDA further updated its recommendation to say,"All GBCAs may be associated with some gadolinium retention in the brain and other body tissues. However, because we identified no evidence to date that gadolinium retention in the brain from any of the GBCAs, including GBCAs associated with higher retention of gadolinium, is harmful, restricting GBCA use is not warranted at this time."
As part of the Friday meeting, FDA officials asked panel members to suggest future directions for research, a hint that the agency may impose more requirements on manufacturers. Members recommended patient registries and epidemiological and animal studies.


TAGS:  MedPage Today, Shannon Firth, MRI, gadolinium, FDA

Friday, September 8, 2017

Pennsylvania Pharmaceutical Assistance Contract to the Elderly (PACE/PACENET)

We received the following letter from the State of Pennsylvania Department of Aging.

The program is funded by the Pennsylvania State Lottery so one would think it is a good benefit for eligible Senior Citizens. But look at the terms and conditions closely! I would not agree to let any one have that carte blanche use of any of my personal health information. I have highlighted provisions I find a bureaucratic over-reach by the State of Pennsylvania. I have also added a few comments (in red).

Would you agree to these terms if they were offered by any other entity? Why the would I agree to them for the State of Pennsylvania?   

CERTIFICATION AND AUTHORIZATION STATEMENTS
Please Read this Information Carefully
I understand that my signature on the application indicates my agreement to the following
provisions:
A.    I authorize the Department of Aging, within its discretion, to release any and all
information in my PACE file as deemed appropriate by the Department
. I authorize such
release of information.
Do whatever you want whenever you want!
B.     I understand that PACE may provide general information including drug claims and
utilization data to outside sources for research purposes, as deemed appropriate by the
Department
. More personal healthcare information released, "as deemed appropriate by the Dept of Aging."
C.     I hereby assign to the Commonwealth of Pennsylvania, in the event of duplicate or
overpayment
, any right to drug benefits to which I may be entitled under any other plan of
government assistance or
insurance from any for-profit third party in-surer. Assign any right to drug benefits to which I may be entitled under any other plan
D.    I hereby waive the confidentiality of any health care information found in any Medicare
Advantage plan (HMO), third party insurer's file or any other information from any health
care source about my medications as witnessed by my signature on this application
. I
authorize such release of information for use consistent with this application. I
understand that PACE may contact my physician for relevant medical history and
information related to my prescription drugs paid for by PACE
. I waive the confidentiality
of such medical records and authorize their release to the PACE program
.   I hereby waive the confidentiality of any health care information found in any Medicare Advantage plan (HMO), third party insurer's file or any other information from any health care source about my medications 
E.     I agree to forgo any payment from any insurance company for any amount which has
been paid by PACE on my behalf.
F.      I authorize the Internal Revenue Service, the Social Security Administration, the U.S.
Railroad Retirement Board, the PA Dept. of Revenue, the PA Dept. of Transportation, the
Public School Employees' Retirement System, the State Employees' Retirement System,
any other federal or state agency and any other financial or other institution or entity with
information on my income or resources to release information to the PACE program that
will verify my eligibility for the PACE program or for the low income subsidy of the federal
Medicare prescription drug benefit
-All information released to the Department of Aging
shall remain confidential in accordance with 72 P
.S. § 3761-517(b).
G.    I authorize the Department of Aging or its designee to act as my representative for
determining my eligibility and applying for the low income subsidy of the Medicare
prescription drug benefit, enrolling me in the Medicare prescription drug plan that best fits
my prescription needs, handling any and all aspects of Part D on my behalf consistent
with federal law, and, if I am a PACE enrollee, paying the premium of the selected
Medicare prescription drug plan that is less than or equal to the regional benchmark
premium.
Enrolling me in the Medicare prescription drug plan that best fits my prescription needs, handling any and all aspects of Part D on my behalf consistent with federal law,

Where the applicant(s) executed a Power of Attorney or is adjudicated incapacitated, the
Department of Aging shall accept the Attorney-In-Fact or court-appointed Guardian as an
authorized agent for the purpose of documenting enrollment
. Power of Attorney or
Guardianship documentation must be provided. 

Wednesday, September 6, 2017

The Pennsylvania Living Home Tax credit, PA Senate Bill 853

The Livable Home Tax Credit SB 853 . Was introduced in the Senate on August 29, 2017. This legislation would create a tax credit t0 be used to retrofit current homes for accessibility or help toward the purchase of a new accessible home.  The credit would be for up to $5,000 and can be carried over for seven years. The credit has a $1,000,000 annual cap.

According to the Center for Universal Design, the expense for one modification can be as high as $50,000. This bill will alleviate some of the financial burden that comes with making a home accessible and most importantly, safe for its residents. The National MS Society supports this bill because it would help people with MS stay in their homes with dignity and independence while remaining active, productive members of their communities.

Tuesday, September 5, 2017

Senators Casey and Toomey, Support Please

Support the bipartisan Durbin-Blunt Amendment to the National Defense Authorization Act (NDAA), when the Senate considers the bill this week

The NDAA reauthorizes the Congressionally Directed Medical Research Programs, including the MS Research Program (MSRP).

The Durbin-Blunt Amendment will remove language in the NDAA that threatens the existence of the MSRP.


As currently written, the NDAA would prohibit funding for medical research by DoD unless such research meets very narrowly defined criteria and places unnecessary and burdensome red-tape acquisition compliance and auditing requirements on research programs within the DoD.  The Durbin-Blunt Amendment would nullify Sections 733, 891, 892, and 893 of the NDAA.

I functioned as a reader (evaluator) in 2016 for MSRP Grant Applications and as a Veteran with a Multiple Sclerosis diagnosis (one of 20,000 veterans know to the VA with the diagnoses). We need the research!

Saturday, September 2, 2017

Senator Browne,

Pennsylvania State Senator Patrick Browne,
During the Pennsylvania Chapters of the National MS Society State Action Day one of our priories was the Livable Home Tax Credit. At the time, only the House version had been introduced. As you are aware the Senate version (SB 853) was introduced on August 29, 2017.
As a member of the Pennsylvania Chapters of the National MS Society Government Relations Advisory Committee and an individual affected by Multiple Sclerosis, I thank you for co-sponsoring SB-853 the Livable Home Tax Credit. Home modification is a costly endeavor and the costs escalate as a person’s disabilities progress. But it is more cost effective for an individual to stay in the home than it is to have them reside in an assisted living facility.

Thank you,


Friday, September 1, 2017

Thank You Congressman Murphy



Congressman Murphy,

Thank you for meeting with Kristen O'Toole and I August 31st, making yourself available to us to once again review the National Multiple Sclerosis Society’s current legislative priorities. As both MS Activists and constituents we welcome the opportunity to discuss these matters with our Member of Congress.

The issues we presented were:

  • FY 2018 NIH funding, the Society seeks a $2 billion increase in funding from 2017 levels.

  • FY 2018 MSRP (MS research within the CDMRP), the Society seeks an increase to $10 million in the FY 2018 budget. This is a $4 million increase over FY 2016 funding. And the MSRP was unable to administer research grants in FY 2017 due to having the federal government operating under a continuing resolution.
This veteran is keenly aware that more investment in research is needed. On average, fewer than 15% of research applications submitted to the MS CDMRP were funded annually between FY 2009 and FY 2014.  

  • Provide $5 million in FY 2018 for the CDC’s National Neurological Conditions Surveillance System. The System was included in the 21st Century Cures Act (Public Law No. 114-255). 21st Century Cures authorized $5 million per year from 2018 thru 2020 for system implementation.

  • Please cosponsor the FAIR Drug Pricing Act (H.R. 2439)  The act would require manufacturers to submit a transparency & justification report before a price increase of 10% in a 12 month period or more than 25% in a 36 month period. The average price of MS disease modifying therapies has increased from $16,000/yr. in 2004 to $83,688/yr in 2017.  

The time committed to our meeting is greatly appreciated. And if you have occasion to need the perspective of an individual with MS or a chronic disability, all you need do is ask!  

Sincerely

Frank Austin
(412) 315-9158

cc: Kristen O’Toole